Back to top
more

IGM Biosciences (IGMS)

(Delayed Data from NSDQ)

$1.31 USD

1.31
487,358

+0.04 (3.15%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $1.31 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -109.76% and 91.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -6.52% and 122.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 337.50% and 235.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround

by Zacks Equity Research

IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -23.17% and 123.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of 1.20% and 58.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amgen (AMGN) Beats Q3 Earnings Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 9.20% and 0.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy

by Zacks Equity Research

IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -2,733.33% and 97.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -10.98% and 7.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immunome (IMNM) delivered earnings and revenue surprises of -28.95% and 9.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of 1.19% and 30.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings

by Zacks Equity Research

Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.

Zacks Equity Research

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 48.39% and 2.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings

by Zacks Equity Research

The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 5% and 13.77%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?